pI: 5.6647 |
Length (AA): 459 |
MW (Da): 50547 |
Paralog Number:
1
Signal peptide: N | GPI Anchor: | Predicted trans-membrane segments: 10
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
PDB Structures:
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Lower 20-40% percentile | Procyclic, Bloodstream Form. | Siegel TN |
Siegel TN | Genome-wide analysis of mRNA abundance in two life-cycle stages of Trypanosoma brucei and identification of splicing and polyadenylation sites. |
Ortholog group members (OG5_127527)
Species | Accession | Gene Product |
---|---|---|
Brugia malayi | Bm1_35820 | Hypothetical transporter C09D4.1 |
Brugia malayi | Bm1_16170 | Major Facilitator Superfamily protein |
Caenorhabditis elegans | CELE_C09D4.1 | Protein C09D4.1, isoform B |
Caenorhabditis elegans | CELE_B0416.5 | Protein B0416.5, isoform B |
Caenorhabditis elegans | CELE_C42C1.8 | Protein C42C1.8 |
Drosophila melanogaster | Dmel_CG1358 | CG1358 gene product from transcript CG1358-RD |
Echinococcus granulosus | EgrG_001130300 | feline leukemia virus subgroup C |
Echinococcus multilocularis | EmuJ_001130300 | feline leukemia virus subgroup C |
Homo sapiens | ENSG00000119686 | feline leukemia virus subgroup C cellular receptor family, member 2 |
Homo sapiens | ENSG00000169026 | major facilitator superfamily domain containing 7 |
Homo sapiens | ENSG00000162769 | feline leukemia virus subgroup C cellular receptor 1 |
Leishmania braziliensis | LbrM.03.0370 | MFS transporter, putative |
Leishmania braziliensis | LbrM.17.1580 | hypothetical protein, unknown function |
Leishmania donovani | LdBPK_171550.1 | major facilitator superfamily, putative |
Leishmania donovani | LdBPK_030390.1 | MFS transporter, putative |
Leishmania infantum | LinJ.03.0390 | MFS transporter, putative |
Leishmania infantum | LinJ.17.1550 | hypothetical protein, unknown function |
Leishmania major | LmjF.03.0410 | MFS transporter, putative |
Leishmania major | LmjF.17.1430 | hypothetical protein, unknown function |
Leishmania mexicana | LmxM.03.0410 | |
Leishmania mexicana | LmxM.17.1430 | hypothetical protein, unknown function |
Loa Loa (eye worm) | LOAG_02657 | hypothetical protein |
Loa Loa (eye worm) | LOAG_03795 | major facilitator superfamily transporter |
Mus musculus | ENSMUSG00000066595 | major facilitator superfamily domain containing 7B |
Mus musculus | ENSMUSG00000029490 | major facilitator superfamily domain containing 7A |
Mus musculus | ENSMUSG00000034258 | major facilitator superfamily domain containing 7C |
Schistosoma japonicum | Sjp_0212580 | ko:K08220 MFS transporter, FLVCR family, feline leukemia virus subgroup C, putative |
Schistosoma japonicum | Sjp_0090710 | Major facilitator superfamily domain-containing protein 7-a, putative |
Schistosoma mansoni | Smp_090220 | feline leukemia virus subgroup C receptor-related |
Schistosoma mansoni | Smp_143690 | feline leukemia virus subgroup C receptor-related |
Schmidtea mediterranea | mk4.017148.00 | Feline leukemia virus subgroup C receptor-related |
Schmidtea mediterranea | mk4.003761.03 | Feline leukemia virus subgroup C receptor-related |
Trypanosoma brucei gambiense | Tbg972.10.4220 | hypothetical protein, conserved |
Trypanosoma brucei | Tb11.v5.1021 | variant surface glycoprotein (VSG), putative |
Trypanosoma brucei | Tb927.10.3350 | major facilitator superfamily, putative |
Trypanosoma congolense | TcIL3000_10_2790 | hypothetical protein, conserved |
Trypanosoma cruzi | TcCLB.510309.20 | MFS transporter, putative |
Trypanosoma cruzi | TcCLB.511421.210 | hypothetical protein, conserved |
Trypanosoma cruzi | TcCLB.506669.4 | MFS transporter, putative |
Trypanosoma cruzi | TcCLB.503505.20 | MFS transporter, putative |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
Tb927.10.3350 | Trypanosoma brucei | significant loss of fitness in bloodstream forms (3 days) | alsford |
Tb927.10.3350 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (6 days) | alsford |
Tb927.10.3350 | Trypanosoma brucei | no significant loss or gain of fitness in procyclic forms | alsford |
Tb927.10.3350 | Trypanosoma brucei | no significant loss or gain of fitness in differentiation of procyclic to bloodstream forms | alsford |
CELE_B0416.5 | Caenorhabditis elegans | slow growth | wormbase |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.